Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00290394
• Date of registration: 09/02/2006
• Primary sponsor: Baskent University
• Public title: Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients
• Scientific title: Study of PPAR Gamma Agonist-Rosiglitazone in Normotensive Type 2 Diabetics With Ambulatory Blood Pressure Monitoring
• Date of first enrolment: March 2004
• Target sample size: 25
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00290394
• Study type: Interventional
• Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Countries of recruitment

Turkey

Contacts

• Name: Neslihan B Tutuncu, MD
• Affiliation: Medical Doctor, Endocrynology

Key inclusion & exclusion criteria

Inclusion Criteria:

- Blood pressure of patients were in normotensive limits according to the JNC VII

- Diabetes mellitus treated with oral antidiabetics or diet

Exclusion Criteria:

- Any known hypertension, coronary artery disease, congestive hearth failure, renal
disease or liver disease

- Anti-hypertensive treatment



Age minimum: 49 Years
Age maximum: 65 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Diabetes Mellitus, Type 2

Intervention(s)

Drug: rosiglitazone(drug), blood pressure lowering effect

Primary Outcome(s)

Ambulatory blood pressure monitors used to determine the subjects blood pressure before and after the treatment. At the end of three months period wit rosiglitazone treatment diastolic blood pressure decreased.

Secondary ID(s)

KA03/181

Source(s) of Monetary Support

Please refer to primary and secondary sponsors